3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
3
Phase 1
3
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Polycystic Ovary Syndrome
2
Pancreatic Neoplasms
2
Melanoma
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Infertility
1
Hereditary Sensory and Autonomic Neuropathies
1
Glioma
1
Chondrosarcoma
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Breast Diseases
1
Interventions
pembrolizumab
44
Nivolumab
29
Gemcitabine
28
Paclitaxel
19
Cisplatin
18
Ipilimumab
15
Carboplatin
14
Cyclophosphamide
13
Capecitabine
12
Dexamethasone
10
Bevacizumab
10
cemiplimab
9
Irinotecan
9
Docetaxel
9
Albumin-Bound Paclitaxel
9
130-nm albumin-bound paclitaxel
9
spartalizumab
8
Pemetrexed
8
Sorafenib
7
Rituximab
7
Cetuximab
7
fludarabine
6
Temozolomide
6
Taxes
6
Radiotherapy
6
Leucovorin
6
Fluorouracil
6
Azacitidine
6
Ascorbic Acid
6
lenvatinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms
×
Metformin
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled